My take on today’s 8k and 10Q is that there has been

New Post Public Reply Private Reply Replies (1) Message Board
Mo
724
My take on today’s 8k and 10Q is that there has been relatively minor dilution by IPIX as they position themselves to finalize a large non-dilutive funding transaction. IPIX has established an emergency safety net of $400k/month from June through October. If we look at the facts we own a piece of a company that has a phase3 ready drug with a strong possibility of success in a market that is $600M-$1.2B ANNUALLY for a single instance. The Brilacidin franchise drug could have several multiple billion dollar revenue streams. We have a cancer drug Kevetrin that will be a game changer in cancer treatment if it makes it to market and would be worth many billions in revenue and profits. The fact that IPIX management has advanced the science to this point with less than 200M total shares outstanding is an impressive feat.

Rollercoaster trading days force investors to take a step back and to reflect WHAT they own and WHY they own an investment. I cannot speak for anyone besides myself but the reason I invested in CTIX starting in 2011 and have continued to add to my position was to make money on my investment. To fully monetize and maximize your investment return with a pre-revenue biotech investment you need to target an exit strategy that begins AFTER a drug makes it to market. An investment in IPIX is a belief that IPIX’s drugs make it through FDA trials and to market where they will produce revenue. An investor must also believe that IPIX management is honest, competent and is looking out for shareholders best interests. If you don’t believe in both the products and in management you really have no business owning IPIX shares. If you do believe that IPIX has competent and honest management and that there is a strong likelihood that these drugs will make it to market, then why should we be concerned with any short-term noise?

This target audience for this post is for investors. I really don’t care what stock traders (legal or illegal) believe. Anyone who has been around for any length of time knows that there is a criminal element that has been attacking our company. It doesn’t take much common sense to simply look at the SMB’s and see that there are posters that are either paid to post negatively or post as part of an overall trading gang to influence IPIX SP. The criminals are very predictable and like to use terms like “bogyman” to discredit the obvious. The other board is full of these cockroaches and Hangout has its share as well. A recent example is a very informative post by 4kids that exposes exactly what the criminals are doing to our company that had 17 likes was stickied by an honest moderator Drano and soon after was taken down by a dishonest moderator and replaced with a post with 2 likes. Do the criminals think we are stupid and don’t know what they are doing? As investors we really don’t know what is going to happen short term. There is just as good of a chance that NSS does another Mako type hit piece on Monday of next week as there is of IPIX announcing a major financing deal. For true investors IT DOESN’T MATTER! Anyone who doesn’t clearly see this is either extremely naïve or they are part of the criminal activity. It is also a fact that the criminals, NR or NSS (these terms are interchangeable) control IPIX’s share price. They have been in control for 5 years initially up and mostly on the way down. Share Price is the ONLY thing that they control using compression with false volume. They cannot control IPIX science, although they have been successful slowing the progression of the science by making it much more costly to fund trials and advancement. The criminals do not control when investors sell their shares although they do their best to shake out weak hands. Any investor with GTC orders will get ripped off every time IPIX SP stages a run as NSS is upside down on IPIX and needs REAL shares. As investors we decide for ourselves when to sell. IPIX is a milestone based company and IPIX has hit many milestones leading us to where we are today with a phase3 ready drug. Now answer the obvious question of value forgetting about how artificially depressed our share price is. Is IPIX worth as much today as it will be once ANY of these individual milestones are achieved? What will our SP be upon completion of ANY/SOME/ALL of the following?

- Large non-dilutive funding becomes available – Could come in MANY forms including royalty based license deal with BP or possibly a creative subsidiary spin-off or Angel investment just to name a few.

- After the start of a B-OM phase 3

- After an Up List to NASDAQ

- After initiating of B-IBD Phase 3

- After completion of B-OM phase 3

- After initiation of a large K phase 2

- After receiving the first ANNUAL royalty check for $100M

- After a 2nd monster license deal for Kevetrin

- After having multiple streams of revenue in the 100’s of millions and becoming a double threat as both a high growth biotech as well as an earnings machine.

This is just a SAMPLE LIST of a few near term milestones. NSS is just as aware of the above list as legit investors are. NSS is also aware that every time IPIX meets one of the above milestones that NSS lose more of their control over IPIX SP. We saw a very small sample of that the other day with trading of 2.5M shares taking it up 89% in a single day. What happens when IPIX secures a major non-dilutive funding agreement and the bashers lose their #1 argument of financial viability and their #2 argument of dilution? How much more valuable is our company as IPIX management executes each milestone from above? If a flood of NEW investors come in large waves with millions in LEGIT volume what will that do to our little thinly traded company? If existing shareholders hang tight until some of the above milestones are met where is the supply of shares going to come from to match the massive demand? When we UP List and there is a MAJOR SHORT SQUEEZE what will happen to our artificially compressed share price? Why would we sell our shares before we take back control of our company as it becomes more fairly valued and products become monetized? In the meantime ignore the noise and use the criminal’s activities against them by adding to your position with artificially compressed prices. There are not many trading days left to do that IMO.
1

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 6

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 3

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 4

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 3

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 3

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 7

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 4

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Food Holdings Transforms Strategies for Future Growth

Updated Category News Views 235

Innovative Food Holdings Sets New Directions for Future Growth Innovative Food Holdings, Inc. (OTCQB: IVFH), based in Broadview, Illinois, isa prominent vendor of specialty gourmet foods targeted at professional chefs.The company recently indicated the timeline for its annual meeting of shareholdersand shared an insightful letter from its CEO, Robert W. (Bill)...

Continue Reading
LET Mining Introduces Innovative BTC Cloud Mining Contracts

Updated Category News Views 141

LET Mining Revolutionizes Passive Income with Cloud Mining Contracts Recently, the cryptocurrency world has witnessed a significant uptick in Bitcoin prices, reaffirming its status as the digital gold of our time. LET Mining, a leader in cloud mining solutions, has risen to the occasion by launching innovative BTC cloud mining contracts designed to turn Bitcoin holdings...

Continue Reading
Alvotech and Teva Move Forward with Proposed AVT06 Biosimilar

Updated Category News Views 229

Alvotech and Teva Collaborate on a New Biosimilar Alvotech (NASDAQ: ALVO), a pioneering biotech firm known for its innovative work in biosimilar medicines, partners with Teva Pharmaceuticals to announce a significant update regarding AVT06, their proposed biosimilar to the widely recognized Eylea (aflibercept). The recent acceptance of their Biologics License Application...

Continue Reading
C4 Therapeutics Strengthens Governance with New Incentive Amendments

Updated Category News Views 85

C4 Therapeutics Reinforces Shareholder Rights with New Amendments C4 Therapeutics, Inc. (NASDAQ:CCCC), a notable biotechnology company, has recently made impactful changes to its stock incentive plan. This amendment aims to improve corporate governance by preventing the lowering of exercise prices for stock options without obtaining prior approval from shareholders....

Continue Reading
ABM Reports Fourth Quarter Results and 2025 Financial Outlook

Updated Category News Views 326

ABM Reports Fourth Quarter and Full Fiscal Results ABM (NYSE: ABM), a recognized leader in facility solutions, recently shared its financial results for the fourth quarter and the complete fiscal year. In the fourth quarter, the company achieved remarkable revenues of $2.2 billion, showcasing an organic growth rate of 3.2%. This marks a significant turnaround and aligns...

Continue Reading